Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.49 |
| ▸ | PGR | P06401 | 4/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KIF5B | P33176 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732615 | 0.93 | NR3C1 (0.44) | NR3C1PGRNR3C2TRPV1 | |
| SCHEMBL5777869 | 0.93 | NR3C1 (0.56) | NR3C1PGRNR3C2 | |
| SCHEMBL5780477 | 0.90 | NR3C1 (0.60) | NR3C1PGRNR3C2 | |
| SCHEMBL5777188 | 0.90 | NR3C1 (0.49) | NR3C1PGRNR3C2TRPV1RAF1 | |
| SCHEMBL5800297 | 0.88 | NR3C1 (0.48) | NR3C1PGRNR3C2TRPV1 | |
| SCHEMBL5777416 | 0.88 | NR3C1 (0.55) | NR3C1PGRNR3C2 | |
| SCHEMBL6404831 | 0.88 | NR3C1 (0.52) | NR3C1PGRNR3C2TRPV1RAF1 | |
| SCHEMBL6405053 | 0.88 | NR3C1 (0.55) | NR3C1PGRNR3C2RAF1BRAF | |
| SCHEMBL5774962 | 0.86 | NR3C1 (0.46) | NR3C1PGRNR3C2TRPV1RAF1 | |
| SCHEMBL5778544 | 0.85 | NR3C1 (0.68) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008055709-A1 | INDAZOLE AND INDOLE DERIVATIVES AS ANTI -INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921068-A1 | Indazole and indole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1638945-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NR3C1 1483/4885PGR 3289/4885NR3C2 872/4885 |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | NR3C1 540/4885PGR 400/4885NR3C2 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.